洞察
Insights From Our Experts
Articles
The Evolution of HTA and Its Impact on Drug Prices in Japan
Health Technology Assessment Status in Japan Health technology assessments (HTAs) are increasingly used worldwide to assess the clinical and economic impact of drug treatments and technologies, inform health policy, and guide drug pricing and reimbursement. In…
Elevate Your Brand to New Heights by Utilizing National Account Managers’ Singular Skills, Resources and Experience in an Ever-changing Marketplace
Launching new therapies is a vast undertaking for any pharmaceutical company. Setting up a product for success requires a great deal of expense, research, strategic planning and effective collaboration, just to name a few essential elements. EVERSANA’s National…
Against the Odds: Managing the Uncertainty of FDA Approval for Emerging Companies
47% of FDA applications are delayed for resourceful larger pharma. The situation is even worse for emerging pharma, with 78% of FDA applications being delayed. Pharmaceutical companies have seen a steady and daunting rise in…
The New Role of Medical Field Teams and Their Impact on Launch Success
A combination of industry challenges and an influx of complex therapies in the market, have impacted Medical Science Liaisons (MSLs), Clinical Trial Liaisons (CTLs) and Clinical Nurse Educators (CNEs). Susan Giacalone, MSN, BCMAS, MSL-BC, Vice President,…
Leveraging Salesforce Marketing Cloud Personalization to Power the Next Generation Rep
Life sciences companies need to shift from the mindset of a pharmaceutical manufacturer of the twentieth, to that of the digital healthcare company of the twenty-first. Reps remain important, but they need to be empowered to succeed.…
How Specialty Pharmacies Can Elevate Your Channel and Distribution Strategy for HCP-administered Buy & Bill Products
A successful channel and distribution strategy for Buy & Bill (B&B) products should be centered around the partners you sell to and through. That means considering any third-party logistics (3PL) providers, specialty distributors (SD) and specialty…
AMA Scheduled to Deliberate Potential Approval of Additional Digital Medicine CPT Codes
As part of its upcoming meeting in mid-September, members of the American Medical Association’s (AMA) CPT Editorial Panel will consider several new Current Procedural Terminology (CPT) codes that identify digital diagnostic and therapeutic procedures. Between this…
Point of Attack: Developing a Targeted Oncology Account Engagement Strategy and Tactical Platform
Key account management (KAM) is a more innovative approach to pharmaceutical sales and account engagement. KAM promises to deliver long-term, mutually beneficial partnerships between biopharmaceutical manufacturers and healthcare systems and provider practices (aka target accounts). Pharmaceutical…
Reimbursement Landscape for Digital Medicine Continues to Advance with CMS
The Centers for Medicare and Medicaid Services (CMS) recently announced several new payment and coding proposals that, once finalized, would recognize and advance the use of digital diagnostic and therapeutic modalities. In this week’s update, we…
Connectivity Between Field Reimbursement Managers and Patient Services: The Missing Link to Efficiency
EVERSANA’s Rich Heddens, Senior Vice President, Payer Strategy & Execution, and Matthew Baniak, Vice President, Client Delivery & Excellence, discuss the importance of connectivity between Field Reimbursement Managers (FRMs) and Patient Services. Disparate information, antiquated systems…